Female sexual dysfunction (FSD) is thought to affect around 43 per cent of women, yet a recent report suggests it could be a figment of the drug industry’s imagination. Are these concerns justified, or is it a real condition?

The idea that FSD may be a marketing ploy surfaced in a recent issue of the British Medical Journal, where Australian journalist Ray Moynihan suggested drug companies had created the disorder, through close ties with researchers, as a way to market medication.

‘The potential risk, in a process so heavily sponsored by drug companies, is that the complex social, personal and physical causes of sexual difficulties – and the range of solutions to them – will be swept away in the rush to diagnose, label and prescribe,’ claimed Ray

Link